Document is current
Any future updates will be listed below
-
Authors
Hou, Junlei
Xie, Shuanglong
Gao, Jianbao
Jiang, Tao
Zhu, Enjian
Yang, Xuezhi
Jin, Zheng
Long, Haixia
Zhang, Anmei
Yang, Fei
Wang, Lujing
Zha, Haoran
Jia, Qingzhu
Zhu, Bo
Wang, Xinxin
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81925030, 82273213)
National Nature Science Foundation of China (81821003)
- License Information
-
More Information
Article History
Received: 19 December 2023
Accepted: 8 April 2024
First Online: 9 May 2024
Declarations
:
: All in vivo experiments adhered to the institutional ethical guidelines on animal care and were approved by The Institutional Animal Care and Use Committee of TMMU. The tumor cannot exceed 2000 mm<sup>3</sup> in mice, and the diameter of any dimension is less than 20 mm. We ensure that all mouse tumors do not exceed the maximum tumor size/burden. The clinical information of the immunotherapy cohort of patients with aNSCLC was approved by the Ethics Committee of Shanghai Pulmonary Hospital affiliated with Tongji University (K18-136).
: All authors have known and agreed to publish.
: <sup>1</sup>Institute of Cancer, Xinqiao Hospital, Third Military Medical University; Chongqing, 400037, China.<sup>2</sup>Shanghai Pulmonary Hospital, Shanghai, 200082, China.<sup>3</sup>Department of Oncology, PLA Rocket Force Characteristic Medical Center; Beijing, 100088, China.<sup>4</sup>Jinfeng Laboratory; Chongqing, 401329, China.
: The authors declare no competing interests.
